#1 Clinical Trials Search in Europe

REGN7999

REGN7999 is an experimental drug currently being studied in clinical trials for its potential to regulate iron levels in the body. The drug works as a TMPRSS6 antagonist (inhibitor), which may help control iron metabolism. Clinical trials are examining REGN7999 in both healthy individuals and patients with non-transfusion dependent beta-thalassemia (NTDT), a genetic blood disorder that can lead to iron overload. These trials are designed to evaluate the drug’s safety profile, how it works in the body, and its effectiveness in reducing excessive iron levels in patients with NTDT.

Table of Contents

What is REGN7999?

REGN7999 is an experimental medication currently being studied in clinical trials. It is classified as a TMPRSS6 antagonist, which means it works by blocking the activity of a protein called TMPRSS6 (Transmembrane Protease, Serine 6) in the body[1]. REGN7999 is being developed as a potential treatment for conditions involving iron overload, particularly in patients with a genetic blood disorder called non-transfusion dependent beta-thalassemia (NTDT)[2].

This medication is administered as an injection, either into a vein (intravenous or IV) or under the skin (subcutaneous or SC). As REGN7999 is still in the research phase, it has not yet been approved by regulatory agencies for general use and is only available to participants in clinical trials[1][2].

How REGN7999 Works

REGN7999 functions as an inhibitor of TMPRSS6, a protein that plays a key role in regulating iron levels in the body. By blocking this protein, REGN7999 may help reduce excessive iron accumulation in various organs and tissues[2].

In conditions like beta-thalassemia, the body can absorb and store too much iron, leading to iron overload. This excess iron can accumulate in vital organs such as the liver, heart, and endocrine glands, potentially causing serious damage over time. REGN7999 aims to address this problem by targeting the underlying mechanisms that contribute to iron overload[2].

Medical Conditions Treated with REGN7999

The primary focus of current clinical research for REGN7999 is Non-Transfusion Dependent Beta-Thalassemia (NTDT). This is a genetic blood disorder characterized by reduced production of hemoglobin, the protein in red blood cells that carries oxygen throughout the body[2].

Beta-thalassemia can vary in severity. Patients with NTDT have a milder form that doesn’t typically require regular blood transfusions for survival. However, these patients can still develop significant iron overload over time, which can cause serious health complications[2].

The clinical trials are specifically examining whether REGN7999 can help reduce iron overload in the bodies of people with NTDT, particularly focusing on liver iron concentration (LIC) as measured by specialized MRI scans[2].

Administration Methods

REGN7999 is administered through two possible routes:

  • Intravenous (IV) injection: The medication is delivered directly into a vein. This method is being tested in some of the clinical trial cohorts[1].
  • Subcutaneous (SC) injection: The medication is injected just under the skin. This method is also being evaluated in clinical trials and is the administration route being used in the beta-thalassemia study[1][2].

The dosing schedule and amount of medication given varies depending on the specific clinical trial and study phase. In current trials, participants receive either REGN7999 or a placebo (an inactive substance) for comparison purposes[1][2].

Clinical Research on REGN7999

REGN7999 is currently being studied in multiple clinical trials to determine its safety, effectiveness, and how it works in the body. These include:

Phase 1 Trial in Healthy Volunteers

A Phase 1 trial (NCT05481333) is evaluating the safety and tolerability of REGN7999 in healthy adult participants. This study is examining:

  • How safe the medication is when given as a single dose
  • How the body processes the medication (called pharmacokinetics)
  • How the medication affects the body (called pharmacodynamics)
  • Whether participants develop antibodies against the medication (called immunogenicity)[1]

This study uses a randomized, double-blind, placebo-controlled design, which means participants are randomly assigned to receive either REGN7999 or a placebo, and neither the participants nor the researchers know who receives which until after the study is complete[1].

Phase 2 Trial in Non-Transfusion Dependent Beta-Thalassemia

A Phase 2 trial (Study ID: R7999-BThal-2350) is specifically testing REGN7999 in adults with non-transfusion dependent beta-thalassemia who have iron overload. This study aims to:

  • Determine if REGN7999 can reduce iron levels in the liver (measured by specialized MRI scans)
  • Assess changes in hemoglobin levels (the oxygen-carrying protein in blood)
  • Monitor the need for blood transfusions
  • Evaluate overall safety and side effects[2]

This study is also randomized and placebo-controlled, with participants receiving different doses of REGN7999 or placebo for comparison[2].

Safety and Side Effects

As REGN7999 is still in the investigational stage, complete information about its safety profile and potential side effects is not yet available. The ongoing clinical trials are specifically designed to collect this important safety information[1][2].

The trials are monitoring for Treatment-Emergent Adverse Events (TEAEs), which are any unfavorable medical occurrences that develop or worsen after receiving the study medication. These events can range from mild to severe and may or may not be directly related to the medication[1][2].

Researchers are also monitoring for the development of anti-drug antibodies (ADA), which are proteins the body might produce in response to REGN7999. These antibodies could potentially reduce the effectiveness of the medication or cause additional side effects[1][2].

Expected Benefits of REGN7999

Based on the clinical trials underway, REGN7999 is being investigated for several potential benefits for patients with non-transfusion dependent beta-thalassemia:

  • Reduction in liver iron concentration: The primary goal is to decrease the amount of excess iron stored in the liver, which is measured using specialized MRI techniques[2].
  • Improvement in hemoglobin levels: Researchers are evaluating whether REGN7999 can increase hemoglobin levels, which could potentially improve oxygen delivery throughout the body[2].
  • Reduced need for blood transfusions: One of the outcomes being measured is whether participants require fewer red blood cell transfusions while taking REGN7999[2].
  • Achievement of transfusion independence: For some patients, the goal would be to eliminate the need for blood transfusions entirely[2].

The current clinical trials are designed to determine whether REGN7999 can effectively deliver these benefits while maintaining an acceptable safety profile[2].

Aspect Details
Drug Name REGN7999
Drug Type TMPRSS6 antagonist/inhibitor antibody
Administration Routes Intravenous (IV) and Subcutaneous (SC)
Current Trial Phases Phase 1 (healthy volunteers), Phase 2 (beta-thalassemia patients)
Target Conditions Iron overload in Non-transfusion Dependent Beta-thalassemia (NTDT)
Primary Outcomes Measured Safety, tolerability, change in liver iron concentration (LIC)
Secondary Outcomes Hemoglobin levels, red blood cell counts, transfusion requirements, drug concentration in blood, antibody development
Trial Duration 20-26 weeks (healthy volunteers), up to 72 weeks (beta-thalassemia patients)
Study Design Randomized, double-blind, placebo-controlled trials

FAQ

  • What is REGN7999 and how does it work? REGN7999 is an experimental antibody that works as a TMPRSS6 antagonist or inhibitor. TMPRSS6 is a protein involved in iron regulation in the body. By blocking TMPRSS6, REGN7999 may help reduce iron overload, which is particularly beneficial for conditions like beta-thalassemia where excess iron accumulation can damage organs.
  • What conditions is REGN7999 being tested for? REGN7999 is currently being tested in healthy volunteers to establish its safety profile and understand how it works in the body. It's also being studied in patients with non-transfusion dependent beta-thalassemia (NTDT) who experience iron overload. This condition is a genetic blood disorder where the body doesn't produce enough normal hemoglobin, leading to anemia and often excessive iron accumulation.
  • How is REGN7999 administered to patients? REGN7999 is administered either intravenously (IV) or subcutaneously (SC). IV administration means the drug is injected directly into a vein, while subcutaneous administration means it's injected just under the skin. The clinical trials are testing both methods to determine the optimal way to deliver the medication.
  • What are researchers measuring to determine if REGN7999 is effective? For patients with beta-thalassemia, researchers are primarily measuring changes in liver iron concentration (LIC) using R2* magnetic resonance imaging (MRI). They're also tracking changes in hemoglobin levels, red blood cell counts, need for blood transfusions, and whether patients achieve transfusion independence. In all participants, they monitor drug concentration in the blood and whether the body develops antibodies against the drug.
  • How long do the clinical trials for REGN7999 last? The duration varies depending on the specific trial. The Phase 1 trial in healthy participants lasts up to 20-26 weeks (about 5-6 months), with follow-up visits to monitor safety. The Phase 2 trial for patients with beta-thalassemia is longer, with key measurements taken at 24 weeks (about 6 months) and 52 weeks (1 year), and some outcomes tracked up to 72 weeks (about 1.5 years).

Ongoing Clinical Trials on REGN7999

  • Evaluation of the Efficacy, Safety, and Tolerability of Subcutaneous REGN7999 in Adults with Iron Overload Due to Non-Transfusion Dependent Beta-Thalassemia

    Not yet recruiting

    1
    Investigated drugs:
    Greece Italy

  • Safety and Tolerability of REGN7999 in Healthy Adult Participants

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

Glossary

  • TMPRSS6: A protein (enzyme) involved in regulating iron levels in the body. REGN7999 works by blocking this protein to help control iron metabolism.
  • Antagonist: A substance that blocks or inhibits the action of something else. REGN7999 is a TMPRSS6 antagonist, meaning it blocks the activity of the TMPRSS6 protein.
  • Beta-thalassemia: A genetic blood disorder that reduces the production of hemoglobin, the protein in red blood cells that carries oxygen. This leads to anemia and often iron overload.
  • Non-transfusion Dependent Beta-thalassemia (NTDT): A form of beta-thalassemia where patients don't regularly require blood transfusions but may still experience complications including iron overload.
  • Iron overload: A condition where too much iron builds up in the body, potentially damaging organs like the liver and heart. This is common in beta-thalassemia patients.
  • Liver Iron Concentration (LIC): A measurement of iron levels stored in the liver, which is used to assess iron overload. In clinical trials, this is measured using specialized MRI techniques.
  • R2* MRI: A specialized type of magnetic resonance imaging used to measure iron concentration in organs, particularly the liver. It's a non-invasive way to monitor iron overload.
  • Intravenous (IV): Administration of medication directly into a vein. Some participants in REGN7999 trials receive the drug this way.
  • Subcutaneous (SC): Administration of medication by injection just under the skin. This is one of the ways REGN7999 is being tested in clinical trials.
  • Treatment-emergent adverse events (TEAEs): Side effects or unwanted events that occur after starting a treatment. Monitoring these is a key part of assessing REGN7999's safety.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated. This helps determine appropriate dosing.
  • Pharmacodynamics: The study of how a drug affects the body, including its mechanism of action and biochemical effects. This helps understand how REGN7999 changes iron metabolism.
  • Anti-drug antibodies (ADA): Proteins produced by the immune system that recognize and bind to a drug. These can potentially reduce the drug's effectiveness or cause side effects.
  • Hemoglobin: The protein in red blood cells responsible for carrying oxygen throughout the body. Levels are often low in beta-thalassemia patients.
  • Transfusion independence: A condition where a patient no longer requires blood transfusions to maintain adequate hemoglobin levels. This is one of the goals for REGN7999 treatment in beta-thalassemia.

References